Skip to main content

Home/ health information/ Group items tagged Development

Rss Feed Group items tagged

pharmacybiz

RPS teams up with Marie Curie charity for community pharmacy - 0 views

  •  
    The Royal Pharmaceutical Society (RPS) has launched a partnership with the charity Marie Curie to develop professional standards in end of life care for community pharmacy. Available for pharmacy teams across the UK, the standards will provide a free, evidence-based framework to help community pharmacies self-assess and continuously improve their end of life and bereavement care for patients and carers. They will enable community pharmacy teams to work together to develop their own practice. RPS is setting up a professional standard steering group which will have community pharmacy experts, experts within the field of palliative and end of life care, lay members, and healthcare professionals who interact with community pharmacy. Elen Jones, director lead for palliative care work at RPS, said: "RPS has a long-term commitment, striving to ensure that people living with life-limiting conditions who are approaching the end of life have timely access to medicines and clinical support from a skilled pharmacy team. "The development of these standards, in partnership with Marie Curie, is a crucial step to support community pharmacy teams to undertake simple quality improvement measures and build upon the care they already provide to this group of patients and carers."
wheelchairindia9

Cp Child Wheelchair - 0 views

  •  
    Pediatric Wheelchair is designed especially for children and offers the maximum in safety and comfort that is sure to put smiles on the faces of parents and children alike.The precision crafted reclining mechanism provides ultra smooth reclining performance and comes standard with swing away detachable elevating legrests. Pediatric wheelchairs are provided unsurpassed quality and style, specializing in compact-folding, lightweight wheelchairs for children of all ages - from toddlers to teens! Custom built to your child's specific needs, our mobility aids offer rehabilitative benefits for physical disabilities from Cerebral Palsy to Autism.
  •  
    Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks. Cerebral palsy causes problems with muscle tone, movement, balance and/or coordination. Symptoms and effects range from mild to severe. In some infants, problems are evident soon after birth. In others, diagnosis comes in later infancy or toddlerhood. Cerebral Palsy Wheelchair Description: The model designed for cerebral palsy child only. Ultra light weight aluminium alloy frame. Seat Width 38 cms (15"). Net Weight: 18.5 kgs. Epoxy powder coated frame. Detachable arm rest & foot rest provided. Elevated and swinging foot rest. Elevated foot rest provided to elevate leg angle. Height adjustable and detachable head rest. Hydraulic reclining high back for a comfortable posture. Hydraulic adjustable seat angle. Detachable back and seat pad. Extra cushion upholstery provided to under arm, head & calg Foldable. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cloth look like water proof upholstery. Anti wheels for better safety and stability. Extra cushion upholstery provided to under arm, head & leg Folding action. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cerebral Palsy Wheelchair Recline system: Recline system provides kids with the most comfortable resting environment. It also allows stretching abdomin
anonymous

Wheelchair : Handicap Products: Cerebral Palsy Information - 0 views

  •  
    Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks related to motor control. Cerebral palsy is the focus of a large amount of medical research every year. Though much of this research deals with younger patients, more and more attention is being paid to CP sufferers as they age and seek fuller opportunities and more integration with the rest of society. Living with CP is a daily challenge, but paths to a richer and more fulfilling life are being found. There is not, and may never be a "cure" for CP, but greater understanding by clinicians and the daily success stories of those who overcome their limitations are making. Buy online CP Wheelchair, Pediatric Cerebral Palsy Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Karma CP Wheelchair, Pediatric Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair at low price in india. Causes of Cerebral Palsy Cerebral palsy is generally caused by developmental issues during pregnancy which lead to abnormal conditions in the brain. During the birth process, lack of oxygen caused by premature delivery or delivery-room errors can cause brain damage that facilitates cerebral palsy. Cerebral palsy can also be caused by recognizable brain injuries sustained by the developing child up to an early
lifelinelab

BREAST CANCER SCREENING - 0 views

  What is screening ? Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may b...

Bestpathologylabs bestpathlabnearme Bestdiagnosticlab diagnosticcenternearme bestdiagnosticcenternearme diagnosticcenter bloodtestathome bloodtestathomenearme bloodonlinetest onlinebloodtest onlinebloodtestlabindelhi thyroidtestathome thyroidtestlabnearme

started by lifelinelab on 07 Dec 18 no follow-up yet
pharmacybiz

Omicron :UK Scientist Backs Vaccines Against it - 0 views

  •  
    The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed. Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent after more research in the coming weeks. "It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio. But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly." In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".
pharmacybiz

Retinoblastoma :NHS rolled out test to treat babies - 0 views

  •  
    NHS England is set to roll out a new test this week that will help doctors to spot a rare form of eye cancer in babies in the womb. The NHS test developed at Birmingham Women's and Children's NHS Foundation Trust, identifies the risk of developing retinoblastoma in babies that can be monitored and treated sooner - increasing the chance of saving their eyesight and potentially their lives. The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk. "The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100 per cent accuracy if the baby will develop retinoblastoma," the NHS said.
pharmacybiz

Future of community pharmacy vision : Nuffield seeks views - 0 views

  •  
    Nuffield Trust and The King's Fund are seeking feedback from community pharmacy on their proposals for the future of community pharmacy and they are seeking feedback from community pharmacy stakeholders. The online survey is the latest opportunity for pharmacy owners, LPCs and others in the sector to engage with the project to develop a Vision for Community Pharmacy. Nuffield Trust and The King's Fund want to hear their views on their proposals, ahead of the publication of the final report later this year. The vision is critically important, as it will be used to develop the future strategy for the sector and lay the groundwork for the next Community Pharmacy Contractual Framework (CPCF) negotiations. The survey is asking for thoughts on key aspects of the vision and its recommendations. The vision has been developed by Nuffield Trust and The King's Fund following an extensive programme of research, interviews and meetings of the vision Steering Group, Advisory Panel, and Working Groups, all of which have contractors, LPCs and other representatives of the sector at their heart. The vision project team are looking forward to hearing views from across the sector on their proposals and what will need to happen to make them a reality.
pharmacybiz

Moderna joins ABPI aims to strengthen its footprint in UK - 0 views

  •  
    Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.
pharmacybiz

Antibiotic may help avoid resistance to dangerous superbugs - 0 views

  •  
    Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.
pharmacybiz

Rosemont strengthens with acquisition of Lucis Pharma - 0 views

  •  
    Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.
pharmacybiz

Department of Health: 'Consultant Pharmacist' role in NI - 0 views

  •  
    The Department of Health has published 'A Guide to Developing the Role of Consultant Pharmacists' in Northern Ireland on Thursday (22 June). The guidance provides direction on supporting a consistent approach to the introduction of senior clinical pharmacy roles within and across HSC organisations. The Chief Pharmaceutical Officer Professor Cathy Harrison said: "There is a recognised need for increased clinical pharmacy and medicines focussed leadership across our HSC." "Consultant Pharmacists have an essential role in healthcare as clinicians and as leaders who make a significant impact to medicines optimisation and clinical governance, providing a vital link between clinical practice and service development by generating and disseminating evidence to drive improvements in care. "I am delighted that this guidance has been published to take forward the strategic development and appointment of the consultant pharmacy workforce in both primary and secondary care and to enable pharmacy to be at the forefront of healthcare in NI".
pharmacybiz

NHS commissions RPS to develop sustainability guidance - 0 views

  •  
    NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment. The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions. "I'm delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams," RPS president Professor Claire Anderson said. "Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving 'net zero' emissions by 2040." Peter Morgan, medicines assistant director at NHS England, commented: "Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices." The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.
manasitsolution

Best web development company in jaipur:: Manas IT Solution - 0 views

  •  
    Manas IT Solution uses the latest technologies available to provide high-quality Website Development, Software Development, Digital Marketing, Social Media Post Design, Industrial Training, Android Applications, and iPhone Applications to end users on a broad range of platforms.
pharmacybiz

RPS publishes new core advanced pharmacist curriculum - 0 views

  •  
    The Royal Pharmaceutical Society (RPS) has published its new 'Core Advanced Pharmacist Curriculum' to enable professional development towards advanced pharmacist practice. This follows an intensive programme of work undertaken in collaboration with a wide range of UK stakeholders, the society said today (June 27) in a statement. The Curriculum will equip pharmacists with advanced leadership, education, and research capabilities which are essential to support, lead and advance the profession through transformative change so it continues to meet evolving patient and service requirements. The RPS Core Advanced Curriculum provides the blueprint to develop such individuals by articulating a UK entry-level standard to advanced pharmacist practice, relevant to all patient-focussed pharmacist roles and aligned to multi-professional definitions of advanced practice. This curriculum completes the core RPS post-registration curricula, creating a seamless post-registration professional development continuum modelled around five common domains- Person-centred care and collaboration; Professional practice; Leadership and management; Education; and Research.
pharmacybiz

Pharma group seeks fairer future access for covid patents - 0 views

  •  
    An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.
pharmacybiz

https://www.pharmacy.biz/news/uk-govt-to-invest-100m-for-developing-ai-powered-solution... - 0 views

  •  
    The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission. UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week. The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI." It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments effectively. Henceforth, it will provide us with better data on how well new therapies work. Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."
pharmacybiz

GSK to buy Affinivax for up to $3.3 bln in vaccines push - 0 views

  •  
    GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.
pharmacybiz

Gordon Cameron : TMC Pharma appointed as director - 0 views

  •  
    Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director. Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis. For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research Organisation. In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry. Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market."
pharmacybiz

8 Reasons/SIgns To See An Endocrinologist - 0 views

  •  
    Endocrinology is the study of hormones and glands in the human body. The endocrine system produces and secretes hormones that regulate many bodily functions, including growth and development, metabolism, and reproductive health. Endocrinologists are physicians who specialize in diagnosing and treating hormonal imbalances and disorders. There are several reasons why you might consider seeing an endocrinologist. In this article, we'll explore some of the most common reasons people seek out the expertise of an endocrinologist. YOU HAVE DIABETES If you have diabetes, it is important to consider seeing an endocrinologist. Endocrinologists specialize in managing diabetes and can help you develop a personalized treatment plan to manage your blood sugar levels. They can also help you prevent or manage complications of diabetes, such as nerve damage, kidney disease, and eye problems. An endocrinologist can work with you to develop a healthy lifestyle plan that includes diet, exercise, and medication management. They can also help you adjust your treatment plan as needed to ensure that your diabetes is well-controlled. Seeing an endocrinologist can help you achieve better health outcomes and improve your overall quality of life.
pharmacybiz

Mundipharma & Vectura Asthma Inhaler Transformation - 0 views

  •  
    Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.
‹ Previous 21 - 40 of 577 Next › Last »
Showing 20 items per page